A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer
- First Posted Date
- 2006-10-29
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 100
- Registration Number
- NCT00393822
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Etanercept
- First Posted Date
- 2006-07-28
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 639
- Registration Number
- NCT00357903
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
Phase 3
Completed
- Conditions
- Secondary HyperparathyroidismChronic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 3883
- Registration Number
- NCT00345839
Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
Phase 2
Completed
- Conditions
- Skin ToxicitiesMetastatic Colorectal CancerSkin RashColon CancerColorectal Cancer
- Interventions
- Biological: PanitumumabDrug: FOLFIRIDrug: Pre-emptive Skin TreatmentDrug: Reactive Skin Treatment
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 95
- Registration Number
- NCT00332163
Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2010-12-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 205
- Registration Number
- NCT00317499
A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2006-02-20
- Last Posted Date
- 2010-03-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 813
- Registration Number
- NCT00293826
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy
Phase 3
Completed
- Conditions
- Anemia
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117624
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 16
- Registration Number
- NCT00117143
Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis
Phase 3
Completed
- Conditions
- Chronic Kidney DiseaseKidney Disease
- Interventions
- Drug: De Novo Administration of Darbepoetin Alfa
- First Posted Date
- 2005-05-30
- Last Posted Date
- 2009-07-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 100
- Registration Number
- NCT00112008
Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Phase 2
Completed
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-05-23
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 45
- Registration Number
- NCT00111475
© Copyright 2025. All Rights Reserved by MedPath